References

problendo

Проблемы Эндокринологии

Problems of Endocrinology

0375-96602308-1430

Endocrinology Research Centre

10.14341/probl201258346-50

problendo-4689

Research Article

Статьи

Articles

Использование препаратов инсулина ультракороткого действия в инсулиновых помпах

The use of ultra-short acting insulin preparations for insulin pumps

Andrianova

E A

katandr13@list.ru

2012

15062012

583

ТОМ 58, №3 (2012)

4650

2012

Andrianova E.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.probl-endojournals.ru/jour/article/view/4689

Представлены данные об эффективности использования препаратов инсулина ультракороткого действия в инсулиновых помпах у детей и подростков c сахарным диабетом. Помповая терапия у детей и подростков находит все более широкое распространение и ассоциирована с улучшением гликемического контроля и удобства для пациентов. Одним из основных преимуществ современной помповой инсулинотерапии является возможность максимально имитировать физиологический профиль инсулиновой секреции. Гибкость дозирования как базисного, так и болюсного режима введения повышается при использовании в помпе препаратов инсулина ультракороткого действия. Использование в инсулиновой помпе любого из трех аналогов инсулина ультракороткого действия обеспечивает идентичную эффективность и безопасность у пациентов детского и подросткового возраста с сахарным диабетом 1-го типа, и могут быть рекомендованы как инсулины выбора для использования в помповой терапии.

The data on the efficacy of using ultra-short acting insulin preparations in insulin pumps for children and adolescents presenting with diabetes mellitus. Insulin pump therapy in the patients of these age groups is finding an increasingly wider application as being more convenient for the users and leading to the improvement of glycemic control. One of the main advantages of modern insulin pump therapy is the possibility to maximally imitate the physiological profile of insulin secretion. The flexibility of both basal and bolus dosing regimens of insulin administration can be further increased by using ultra-short acting insulin preparations in insulin pumps. The choice of any of the three currently available analogs of ultra-short acting insulin guarantees their identical efficacy and safety in the children and adolescents with type 1 diabetes mellitus. They can be recommended as insulins of choice for the use in pump therapy

сахарный диабетдетиподросткипрепараты инсулина ультракороткого действияинсулиновые помпыкомпенсация углеводного обмена

diabetes mellituschildrenadolescentsultra-short acting insulin preparationsinsulin pumpscompensation of carbohydrate metabolis

References1

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.

Diabetes Control and Complications Trial Research Group, The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995; 11336-11351.

The Writing Team for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569.

Writing Team for the Diabetes Control and Complications Trial. Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.

Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. N Engl J Med 2005; 353: 2643-2653.

Ihnat M.A., Thorpe J.E., Ceriello A. Hypothesis: The 'metabolic memory', the new challenge of diabetes. Diabet Med 2007; 24: 582-586.

Емельянов А.О., Кураева Т.Л., Лаптев Д.Н., Петеркова В.А. Проспективное наблюдение эффективности и безопасности помповой инсулинотерапии у детей и подростков. Сахарный диабет 2010; 3(48): 143-146.

Петеркова В.А., Кураева Т.Л., Емельянов А.О. Инсулин Лизпро и помповая терапия у детей и подростков. Педиатрия 2008; 5.

Емельянов А.О., Петеркова В.А., Кураева Т.Л. Трехлетний опыт использования инсулиновых помп в клинической педиатрической практике. Сахарный диабет 2006; 4: 6-8.

Емельянов А.О., Петеркова В.А., Кураева Т.Л. Инсулиновая помпа в лечении сахарного диабета у детей и подростков.Под ред. акад. РАН и РАМН И.И. Дедова. Методические рекомендации. М 2008.

Петеркова В.А., Кураева Т.Л., Емельянов А.О., Андрианова Е.А., Лаптев Д.Н. Помповая инсулинотерапия у детей и подростков. Методическое пособие для педиатров-эндокринологов. М 2011.

Bergenstal R.M., Tamborlane W.V., Ahmann A., Buse J.B., Dailey G., Davis S.N., Joyce C., Peoples T., Perkins B.A., Welsh J.B., Willi S.M., Wood M.A. STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363(4): 311-320.

Fendler W., Baranowska A.I., Mianowska B., Szadkowska A., Mlynarski W. Three-year comparison of subcutaneous insulin pump treatment with multi-daily injections on HbA1c, its variability and hospital burden of children with type 1 diabetes. Acta Diabetol 2011.

Fuld K., Conrad B., Buckingham B., Wilson D.M. Insulin pumps in young children. Diabetes Technol Ther 2010; 12: Suppl 1: S67-S71.

Pańkowska E., Błazik M., Dziechciarz P., Szypowska A., Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009; 10(1): 52-58.

Hirsch I.B., Bode B.W., Garg S., Lane W.S., Sussman A., Hu P., Santiago O.M., Kolaczynski J.W. Insulin aspart CSII/MDI comparison study group: continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28: 533-538.

Tsui E., Barnie A., Ross S., Parkes R., Zinman B. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001; 24: 1722-1727.

Hanaire-Broutin H., Melki V., Bessieres-Lacombe S., Tauber J.P., Study Group for the Development of Pump Therapy in Diabetes. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. Diabetes Care 2000; 23: 1232-1235.

DeVries J.H., Snoek F.J., Kostense P.J., Masurel N., Heine R.J., Dutch Insulin Pump Study Group. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002; 25: 2074-2080.

Arianne C. van Bon, M.D., Bruce W. Bode, M.D., Caroline Sert-Langeron, M.D., J. Hans DeVries, M.D., Ph.D., and Guillaume Charpentier, M.D. Diabet Technol and Therapeutics 2011; 13 (6): 607-614.

Wiefels K., Hubinger A., Dannehl K., Gries F.A. Insulinkinetic and dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analog (B28Asp). Horm Metab Res 1995; 27: 421-424.

Bruce Bode: Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion A randomized study in type 1 diabetes. Diabetes Care 2002; 25: 439-444.

Stuart A., Weinzimer A. Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion of Insulin Aspart Versus Insulin Lispro in Children and Adolescents With Type 1 Diabetes. Diabetes Care 2008; 31: 210-215.

Doyle E.A., Weinzimer S.A., Steffen A.T., Ahern J.A., Vincent M., Tamborlane W.V. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27: 1544-1558.

Weissberg-Benchell J., Antisdel-Lomaglio J., Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26(4): 1079-1087.

Bode B., Weinstein R., Bell D., McGill J., Nadeau D., Raskin P., Davidson J., Henry R., Huang W., Reinhardt R.R. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002; 25(3): 439-444.

Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006; 38(6): 429-433.

David Kerr. Laboratory-Based Non-Clinical Comparison of Occlusion Rates Using Three Rapid-Acting Insulin Analogs in Continuous Subcutaneous Insulin Infusion Catheters Using Low Flow Rates Journal of Diabetes Science and Technology 2008; 2: Issue 3: 450-455

The authors declare that there are no conflicts of interest present.